CJC-1295 + Ipamorelin: The Peptide Clinic Staple That's Never Been Tested as a Combination

The short version

CJC-1295 + Ipamorelin is the most commonly prescribed peptide combination at US anti-aging clinics. Typical cost: $300-800/month.
Zero studies have tested this combination. The synergy rationale comes from a 1990 study that used entirely different compounds.
CJC-1295 reliably elevates growth hormone 2-10x and IGF-1 1.5-3x in human studies. Ipamorelin’s selectivity (no cortisol or prolactin spikes) has only been demonstrated in pigs, not humans.
GH elevation is proven. Downstream outcomes are not. No study using these specific peptides has measured muscle gain, fat loss, sleep improvement, or anti-aging outcomes.
An FDA-approved alternative exists: Tesamorelin has Phase 3 data in 800+ patients showing 15-18% visceral fat reduction. Most people have never heard of it.
There’s a critical confusion almost nobody explains: the CJC-1295 studied in clinical trials (with DAC, half-life 5-8 days) is a completely different compound from what clinics prescribe (no-DAC / Mod GRF 1-29, half-life ~30 minutes).
One death occurred during CJC-1295 clinical trials — a heart attack in an HIV-positive patient. The physician deemed it unrelated to the drug. It ended the pharmaceutical development program anyway.
Both peptides are in regulatory limbo as of April 2026. RFK Jr. announced reclassification, but CJC-1295 specifically may remain restricted due to the cardiac safety signal.

The $500/month question nobody’s asking

Walk into any anti-aging clinic in America. Sit through the consultation. Listen to the pitch about optimizing your growth hormone levels. Nine times out of ten, you’ll be offered CJC-1295 + Ipamorelin.

The pitch sounds great: “Your growth hormone declines as you age. This combination restores youthful GH levels naturally. Better sleep, more muscle, less fat, faster recovery, improved skin. It’s the foundation of peptide therapy.”

Here’s the question they won’t volunteer an answer to: has anyone actually proven that this combination does those things?

The answer is no.

Not “not yet.” Not “the studies are ongoing.” No. Zero studies have tested CJC-1295 and Ipamorelin together. Zero studies using either of these specific peptides have measured muscle mass, fat loss, sleep quality, skin improvement, or any other outcome that clinics promise. The evidence shows that growth hormone goes up. Everything after that is an assumption.

That doesn’t mean it doesn’t work. Thousands of people use this stack and report real benefits — especially improved sleep. But the gap between “this reliably raises GH” and “this produces the outcomes you’re paying $500/month for” is real, and it’s one nobody in the clinic business has an incentive to talk about.

Let’s talk about it.

What these peptides actually are

CJC-1295: A GHRH analog with an identity crisis

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the signal your hypothalamus sends to your pituitary gland telling it to release growth hormone.

Here’s where it gets confusing, and where almost every article about CJC-1295 gets it wrong:

There are two completely different compounds called “CJC-1295.”

CJC-1295 with DAC (Drug Affinity Complex) is the original compound developed by ConjuChem Biotechnologies. The DAC is a chemical modification that binds CJC-1295 to serum albumin in the blood, extending its half-life to 5.8-8.1 days. This is the version used in clinical trials. One injection keeps GH elevated for nearly a week.

CJC-1295 without DAC (also called Modified GRF 1-29, or Mod GRF) is a stripped-down version without the albumin-binding modification. Its half-life is approximately 30 minutes. This is the version nearly every clinic prescribes and every research vendor sells.

These are not the same drug. A compound with a week-long half-life produces sustained, non-pulsatile GH elevation. A compound with a 30-minute half-life produces a brief GH pulse and then clears. The clinical trial data applies to the DAC version. The clinical practice uses the no-DAC version. This disconnect is almost never acknowledged.

Why do clinics use the no-DAC version? Because the brief pulse is considered more physiological — your body releases GH in pulses, not continuous waves. The DAC version’s week-long GH elevation raised concerns about desensitization and was associated with the cardiac adverse event that ended the development program. The no-DAC version is also significantly cheaper to compound.

Ipamorelin: The “selective” GH secretagogue

Ipamorelin is a growth hormone secretagogue — a different class from CJC-1295. While CJC-1295 mimics GHRH (the “release” signal), Ipamorelin mimics ghrelin (the “hunger hormone” that also triggers GH release). They hit the pituitary from two different directions, which is the theoretical basis for combining them.

Ipamorelin’s selling point is selectivity. The landmark study by Raun et al. (1998) showed that Ipamorelin released GH without increasing cortisol, ACTH, or prolactin — even at doses 200x the effective GH-releasing dose. This was a dramatic advantage over older GH secretagogues like GHRP-6 and GHRP-2, which caused cortisol spikes and intense hunger.

The caveat: That selectivity study was conducted in swine. The specific claim that Ipamorelin doesn’t affect cortisol or prolactin in humans has not been rigorously demonstrated in a dedicated human trial. It’s plausible — the receptor pharmacology supports it — but “demonstrated in pigs” is not “proven in humans.”

The combination rationale — sound theory, zero evidence

The logic for combining GHRH analogs with GH secretagogues goes back to Bowers et al. (1990), who showed that co-administration of GHRH and GHRP (growth hormone-releasing peptide) produced greater GH release than either alone — a synergistic effect, not just additive.

The reasoning:

CJC-1295 (GHRH analog) tells the pituitary: “release growth hormone”
Ipamorelin (ghrelin mimetic) tells the pituitary: “be ready to release more growth hormone”
Together, they should produce a larger, more robust GH pulse than either alone

This is pharmacologically sound. But Bowers used GHRH and GHRP-6, not CJC-1295 and Ipamorelin specifically. No published study has tested this particular combination in any model — human or animal.

The CJC-1295/Ipamorelin stack is the most prescribed peptide combination in America, and its evidence base is a 1990 study using different compounds.

What the human evidence actually shows

CJC-1295 (with DAC)

Teichman et al. (2006) — The pivotal study [PMID: 16352683]

37 healthy subjects (age 21-49)
Single subcutaneous injection of CJC-1295 DAC
GH levels increased 2-10 fold for 6+ days
IGF-1 increased 1.5-3 fold for 9-11 days
The effect lasted nearly two weeks from a single injection

Weekly dosing study:

Doses as low as 30-90 mcg/week produced sustained, dose-dependent increases in GH secretion and pulsatility
Confirmed that very small amounts of CJC-1295 DAC can maintain elevated GH levels long-term

No serious adverse events were reported in these studies. Mild side effects included injection site reactions, flushing, and transient fluid retention.

Ipamorelin

Limited human data. A handful of small studies confirm GH release and show a clean side-effect profile:

Mild flushing reported in one study
A pediatric study reported zero side effects
No large, well-powered human trials exist

No major pharmaceutical company has sponsored Phase 3 trials. Novo Nordisk was involved early in Ipamorelin’s development but walked away. The original patents expired, eliminating commercial incentive for the $100-200M investment a Phase 3 program would require.

The clinical trial death

In 2006, during a Phase II trial of CJC-1295 DAC in 192 HIV-positive patients (who were being treated for lipodystrophy), one patient died of a myocardial infarction (heart attack).

The attending physician determined the death was unrelated to CJC-1295, attributing it to the patient’s pre-existing coronary artery disease and elevated cardiovascular risk factors. Some sources cite up to three total cardiac events across the development program.

Despite the physician’s assessment, the event effectively ended CJC-1295’s pharmaceutical development. Biogen Idec terminated their partnership with ConjuChem in 2009. No further industry-sponsored trials have been conducted.

Proponents of the no-DAC version argue that the cardiac event occurred with the DAC formulation (sustained GH elevation for days) and is not relevant to the brief-pulse no-DAC version used clinically. This is a reasonable pharmacological argument but not a proven one.

The outcome gap: GH goes up, but then what?

This is the section that matters most — and the one clinic marketing materials skip entirely.

What’s proven: CJC-1295 reliably elevates GH and IGF-1 in humans. The magnitude is clinically meaningful (2-10x GH, 1.5-3x IGF-1).

What’s assumed but unproven (with these specific peptides):

Claimed benefit	Evidence status
Muscle growth	No study has measured lean mass with CJC-1295 or Ipamorelin
Fat loss	No study has measured body composition changes
Sleep improvement	No study has measured sleep outcomes — though mechanistic support is strong (GHRH promotes slow-wave sleep)
Anti-aging	No study has measured aging biomarkers
Recovery	No study has measured recovery metrics
Skin improvement	No study has measured skin parameters

The assumption is: “GH goes up → IGF-1 goes up → good things happen.” This assumption is reasonable — growth hormone does promote muscle protein synthesis, fat metabolism, and tissue repair. Direct GH injection (HGH) has data showing body composition improvements.

But CJC-1295/Ipamorelin are not direct GH injection. They produce pulsatile GH release at lower absolute levels. Whether this translates to the same downstream outcomes as pharmacological GH doses has not been tested.

User reports suggest it does work — especially for sleep. Improved sleep quality is the most consistently reported benefit across community forums. Body composition changes are described as gradual, typically requiring 3-6 months to become noticeable. Users expecting HGH-like rapid transformation are consistently disappointed.

Why an FDA-approved alternative exists and nobody uses it

Tesamorelin (brand name Egrifta) is an FDA-approved GHRH analog. It has Phase 3 data in 800+ patients showing:

15-18% reduction in visceral abdominal fat
Significant improvements in trunk fat and waist circumference
Increased IGF-1 levels
Good safety profile over 52-week treatment

It’s approved for HIV-associated lipodystrophy, but clinics prescribe it off-label for general visceral fat reduction.

So why does every clinic push CJC-1295/Ipamorelin instead of the one that’s actually FDA-approved?

Cost. Tesamorelin is dramatically more expensive than compounded CJC-1295/Ipamorelin. A new formulation (Egrifta WR) was approved in March 2025 with simplified weekly reconstitution, but pricing remains high.

Dual mechanism. Clinics argue that adding Ipamorelin (a ghrelin-pathway peptide) to a GHRH analog provides a synergy that Tesamorelin alone doesn’t. This is pharmacologically reasonable but — again — untested with these specific compounds.

Access. Tesamorelin requires a prescription specifically for the branded product. Compounded CJC-1295/Ipamorelin is (or will be, post-reclassification) available through compounding pharmacies at a fraction of the cost.

Comparison to alternatives

	CJC-1295/Ipa	Direct HGH	Tesamorelin	MK-677	Sermorelin
Route	SC injection	SC injection	SC injection	Oral	SC injection
Evidence	GH elevation proven; outcomes unproven	Strong Phase 3 data	FDA-approved, Phase 3	Multiple RCTs	Moderate
Cost	$300-800/mo	$500-3,000/mo	High (branded)	$50-150/mo	$200-400/mo
Side effects	Mild (fluid retention)	More significant	Mild-moderate	Hunger, water retention, cortisol	Mild
FDA status	Not approved	Approved	Approved	Not approved	Previously approved (discontinued)
WADA	Banned	Banned	Banned	Banned	Banned

If you want proven outcomes: HGH or Tesamorelin. They have the data.

If you want lower cost and fewer side effects with a reasonable but unproven trade-off: CJC-1295/Ipamorelin. You’re betting that GH elevation translates to the outcomes you want.

If you want oral convenience and don’t mind the appetite increase: MK-677 (Ibutamoren). It has the strongest human evidence among non-approved GH secretagogues (12-month RCTs showing lean mass increases), but increases appetite significantly (it’s a ghrelin mimetic) and can elevate cortisol and prolactin — the side effects Ipamorelin avoids.

Regulatory status — it’s complicated

CJC-1295 and Ipamorelin were placed on the FDA’s Category 2 list in September 2023, banning compounding pharmacies from preparing them.

In February 2026, RFK Jr. announced that approximately 14 of 19 restricted peptides would return to Category 1. However, at FDA Pharmacy Compounding Advisory Committee (PCAC) meetings in October and December 2024, the FDA specifically recommended against including CJC-1295 on the 503A bulks list, likely due to the cardiac safety signal from the DAC trial.

As of April 2026: CJC-1295’s regulatory fate is uncertain. Ipamorelin is more likely to return to Category 1. Neither has a formal rule change published yet. Both remain WADA-prohibited.

Safety — what you need to know

Common side effects (from clinical data and community reports):

Water retention / bloating (peaks weeks 2-4, usually resolves by weeks 6-8)
Flushing / warmth after injection
Tingling or numbness (transient)
Injection site reactions
Hunger increase (more common with less selective GH secretagogues)

Serious considerations:

Insulin resistance: Multiple GH secretagogue trials show increases in blood glucose and HbA1c. If you’re pre-diabetic or diabetic, GH peptides may worsen glycemic control.
IGF-1 and cancer: Chronically elevated IGF-1 is associated with increased cancer risk in epidemiological studies. Acromegaly research shows sustained IGF-1 excess roughly doubles cancer incidence. This is a legitimate concern with any chronic GH-elevating therapy.
Cardiac risk: The CJC-1295 DAC trial death raises an unresolved question about cardiovascular safety, particularly in patients with existing cardiac risk factors.

Monitoring protocol (what responsible clinics should offer):

Baseline and periodic IGF-1 levels (target: upper-normal range, not supraphysiological)
Fasting glucose and insulin
HbA1c every 3-6 months
Comprehensive metabolic panel
Cancer screening appropriate for age and risk factors

Who should NOT use GH peptides:

Active cancer or history of cancer (especially GH-sensitive cancers)
Diabetic retinopathy
Uncontrolled diabetes
Active cardiovascular disease
Pregnancy or breastfeeding
Under 18 (unless under endocrinologist supervision for growth disorders)

The clinic conversation you should have

If you’re considering CJC-1295/Ipamorelin, here are the questions to ask your prescribing physician:

“Which version of CJC-1295 are you prescribing — DAC or no-DAC?” (It should be no-DAC / Mod GRF 1-29)
“What monitoring will you do?” (They should mention IGF-1, glucose, insulin at minimum)
“What outcomes can you point to from clinical trials?” (Honest answer: GH elevation is proven, downstream outcomes are not)
“Why this over Tesamorelin, which is FDA-approved?” (Cost and dual mechanism are legitimate answers; “it’s better” without citing evidence is not)
“What’s your plan if my IGF-1 goes too high?” (They should have a dose-reduction protocol)
“How long do you recommend using this?” (Cycling is common; indefinite use without monitoring is a red flag)

What this means for you

CJC-1295/Ipamorelin reliably raises growth hormone. That much is established. If your goal is to restore age-related GH decline, the mechanism works.
Whether raising GH with these peptides produces the specific outcomes you want is unproven. Sleep improvement has the strongest mechanistic support. Body composition changes are plausible but undemonstrated in clinical trials.
User experience suggests real but gradual benefits. Expect 3-6 months for noticeable body composition changes. Sleep often improves within weeks.
The DAC vs no-DAC distinction matters. Know which one you’re getting and why.
Get monitoring. IGF-1, glucose, and insulin at minimum. Don’t just inject and hope.
Consider the alternatives. Tesamorelin is FDA-approved. MK-677 is oral. Direct HGH has the most outcome data. Each has trade-offs.
This is not a substitute for the basics. Sleep, exercise, nutrition, and stress management do more for your GH levels than any peptide. If those aren’t dialed in, you’re building on a weak foundation.

Sources

Teichman S.L. et al. “Prolonged stimulation of growth hormone and insulin-like growth factor-I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
Raun K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
Bowers C.Y. et al. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984;114(5):1537-1545. PMID: 6423375
Bowers C.Y. “GH releasing peptides — structure and kinetics.” J Pediatr Endocrinol. 1993;6(1):21-31. PMID: 8490810
Bowers C.Y. et al. Synergistic release of GH by GHRH and GHRP combined. Endocrinology. 1990.
CJC-1295 Phase II trial in HIV lipodystrophy — 192 subjects, 1 MI death. ConjuChem Biotechnologies, 2006.
Biogen Idec partnership termination with ConjuChem, 2009.
Murphy M.G. et al. “Effect of alendronate and MK-677 (ibutamoren), a growth hormone secretagogue, on body composition in elderly.” J Clin Endocrinol Metab. 2001. PMID: 11502808
Tesamorelin Phase 3 trial — 404 adults, 10.9% VAT reduction. FDA-approved as Egrifta.
Egrifta WR (tesamorelin F8) — approved March 2025, simplified weekly reconstitution.
FDA PCAC meeting minutes, October 2024 — CJC-1295 recommended against for 503A bulks list.
FDA PCAC meeting minutes, December 2024 — continued Category 2 review.
RFK Jr. announcement, February 27, 2026 (The Joe Rogan Experience) — 14 peptides to return to Category 1.
WADA Prohibited List — CJC-1295 and Ipamorelin prohibited under S2 (Peptide Hormones).
FDA Category 2 bulk drug substance list, September 2023.
Sigalos J.T. & Pastuszak A.W. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual Medicine Reviews. 2018;6(1):45-53. PMID: 28778697
Chapman I.M. et al. “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects.” J Clin Endocrinol Metab. 1996;81(12):4249-57. PMID: 8954023
Nass R. et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-11. PMID: 18981485
Van Cauter E. et al. “Reciprocal interactions between the GH axis and sleep.” Growth Horm IGF Res. 2004;14 Suppl A:S10-7. PMID: 15135771
Colao A. et al. “Systemic complications of acromegaly: epidemiology, pathogenesis, and management.” Endocr Rev. 2004;25(1):102-152. PMID: 14769829
ConjuChem DAC technology platform — CJC-1295 development history.
Novo Nordisk — Ipamorelin early development and discontinuation.